NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

I disagree Hopeforthefuture3, it will not require another DCVax-L trial to get approval for nGBM and rGBM in the EU, Canada and the US.

To use your number of $200,000 per patient, and the following number of annual patients, just for

nGBM, in each country: UK (3,000), EU (13,000), US (13,000), Canada (1,500) = Total of 30,500 nGBM patients per year = $200,000 X 30,500 = $6,100,000,000 ($6.1 billion per year)

That is $6.1 billion in potential annual revenue, just for nGBM approval in the UK, EU, Canada and the US.

If you add another 50% for rGBM ($3.05 billion), the potential annual revenue for nGBM + rGBM, just in the UK, EU, Canada and the US, the total potential annual revenue for Glioblastoma alone is $9,105,000,000 ($9.1 billion).

If you add approval in the rest of the world (ROW), the potential annual global revenue would double to $18.2 billion, just for nGBM and rGBM.

This is solely based on the completed, peer-reviewed and published DCVax-L Phase III trial, with no new or additional trial required.